One of the world's leading academic experts on investing theory and corporate valuation.
Read More
One of the top biotech investors in the world. Record of sixteen $1 Billion+ valuation start-ups.
Read More
Napster's creator, Facebook's first President, Spotify's lead investor, and founder of the Parker Institute for Cancer Immunotherapy.
Read More
Former Chairman and CEO of WellPoint (now Anthem Blue Shield), the largest health insurance company in American history. Federal administrator of Medicare & Medicaid.
Read More
Built Illumina ($55B Mrkt Cap), the world leader in DNA sequencing, and the defining biology tools company of our era.
Read More
Former Chairman and CEO of Novartis, the second-largest pharmaceutical company in the world. Previously CEO of Sandoz. Board member of American Express and Pepsi Co.
Read More
Professor of Genitourinary Medical Oncology and Immunology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. World expert in cancer immunotherapy, having contributed to over 50 publications in clinical research.
Read More
A pioneer in oncology research, and recipient of the Nobel Prize in 2018 for his contributions to the discovery of cancer therapy by inhibition of negative immune regulation.
Read More
The Luis & Nelly Soux Professor of Microbiology at the California Institute of Technology (Caltech). One of the world’s foremost experts in the human microbiome.
Read More
Stanford/Johns Hopkins/NIH-trained physician focused on the applied science of longevity. Ultra-endurance athlete and host of the popular health podcast The Drive.
Read More
25+ years of experience in the life science tools space as both an entrepreneur and investor. Co-founder of life science tools companies Agencourt Bioscience, Agencourt Personal Genomics, and Kapa Biosystems, which generated a combined exit value of $700M.
Read More
Venture capital investor and an acclaimed recording artist who Fast Company named one of the 100 Most Creative People in Business.
Read More
Physician-scientist and one of the world’s most accomplished drug developers, having brought 20+ groundbreaking therapeutics to the market.
Read More
Leveraging an eclectic background in education technology and software M&A, Ryan drives firm investment operations, LP communications, and portfolio management.
Read More